Processing your payment...
Please do not close your browser.

Anti-Infective Ophthalmic Market- Growth, Trends and Forecast 2022 By Product (Levofloxacin, Tobramycin, Ofloxacin, Gatifloxacin, Other), By Application (Prescription Ophthalmic Pharmaceuticals) and By Regions.

29 Jun, 2022 | 137 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the next five years, the Anti-Infective Ophthalmic Market will register a CAGR of 1.1 % in terms of revenue and the global market size will reach USD 1,565 Million by 2029.

Anti-Infective Ophthalmic Market Overview

The increase in ocular surgical procedures is linked to an increased risk of infection. The incidence of bacterial infections after cataracts and refractive surgery is increasing, according to recent studies. The necessity for highly effective new generation antibiotics to treat and prevent serious ocular infections is highlighted by the risk associated with surgical complications such as keratitis and postoperative endophthalmitis. The benefits of postoperative and preoperative antibiotic therapy are highlighted in the most recent Medicare National Surgical Infection Prevention Project regulations.

The development of sophisticated fourth-generation antibiotics has been fueled by an increase in a study on ophthalmic bacterial resistance to previous generation fluoroquinolones. Topical antibiotic medications must successfully pass through the associated ocular tissues to effectively control ophthalmic infections. The vitreous and cornea's avascular characteristics, in particular, limit the absorption of antibiotics into these tissues.

What is our Anti-Infective Ophthalmic Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 1.1 % during the review period (2022 to 2029).

 

By Product

  • Levofloxacin
  • Tobramycin
  • Ofloxacin
  • Gatifloxacin
  • Other

 

By Application

 

 

 

 

  • Prescription Ophthalmic Pharmaceuticals,
  • OTC Ophthalmic Pharmaceuticals

 

 

 

By Companies

  • Santen Pharmaceutical
  • Merck And Co.
  • Roche
  • Pfizer
  • Allergan
  • Novartis

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

 

Historical Year

 

2017 to 2021

Forecast Year

2022 to 2029

Number of Pages

137

 

Customization Available

 

Yes, the report can be customized as per your needs

 

Frequently Asked Questions

What are the current market size and compound annual growth rate (CAGR) of the Anti-Infective Ophthalmic Market during the forecast period (2022-2029)?

The Anti-Infective Ophthalmic Market is growing at a CAGR of 1.1 % over the next 7 years.

Who are the key players in Anti-Infective Ophthalmic Market?

Santen Pharmaceutical, Merck And Co., Roche, Pfizer, Allergan, Novartis, Others.

What region does this Anti-Infective Ophthalmic Market report covers?

  • North America (the United States, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, and Italy)
  • Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
  • South America (Brazil, Argentina, Colombia, etc.)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What is the significant Product of the Anti-Infective Ophthalmic Market?

  • Levofloxacin
  • Tobramycin
  • Ofloxacin
  • Gatifloxacin
  • Other

Who are the Major Players in Anti-Infective Ophthalmic Market?

Market Growth Reports lists out all the Anti-Infective Ophthalmic Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Santen Pharmaceutical, Merck And Co., Roche, Pfizer, Allergan, Novartis, Others

Industry News:

Merck to Acquire Inspire Pharmaceuticals, Inc.

In March 2011, Merck announced that the New Drug Application (NDA) for SAFLUTAN® (tafluprost), an investigational preservative-free prostaglandin analog ophthalmic solution, had been accepted for standard review by the U.S. Food and Drug Administration (FDA). SAFLUTAN is the proposed trade name for tafluprost in the United States.

What are the major Product and Applications for Anti-Infective Ophthalmic Market?

By Product, it is segmented into

  • Levofloxacin
  • Tobramycin
  • Ofloxacin
  • Gatifloxacin
  • Other

By Application, it is segmented into

  • Prescription Ophthalmic Pharmaceuticals,
  • OTC Ophthalmic Pharmaceuticals

Anti-Infective Ophthalmic Market Regional Analysis

Due to the availability of cutting-edge medication formulations there, North America is predicted to dominate the global market for ophthalmic anti-infectives. Another important aspect driving the industry in the area is public health awareness. Because eye infections are becoming more common in the Asia Pacific area, it is expected that the market for ophthalmic anti-infectives would grow quickly. The Middle East and Africa's ocular anti-infective market is projected to have slow development due to low illness awareness and a lack of modern medications and formulations in developing nations including Lebanon, Syria, Cyprus, Turkey, and Iraq.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    1. MARKET DEFINITION
    2. MARKET DYNAMICS
    3. MARKET SEGMENTATION
    4. REPORT TIMELINES
    5. KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
    2. QUALITY CHECK
    3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    1. INTRODUCTION
    2. GLOBAL ANTI-INFECTIVE OPHTHALMIC BY PRODUCT
    3. GLOBAL ANTI-INFECTIVE OPHTHALMIC, BY APPLICATION
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
    2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST OF MATERIALS
    3. OPPORTUNITIES
      1. ANTI-INFECTIVE OPHTHALMIC GROWTH
    4. APPLICATION OF ANTI-INFECTIVE OPHTHALMIC IMPACT OF COVID 19
  5. GLOBAL ANTI-INFECTIVE OPHTHALMIC, BY PRODUCT
    1. INTRODUCTION
    2. LEVOFLOXACIN
    3. TOBRAMYCIN
    4. OFLOXACIN
    5. GATIFLOXACIN
    6. OTHER
  6. GLOBAL ANTI-INFECTIVE OPHTHALMIC, BY APPLICATION
    1. INTRODUCTION
    2. PRESCRIPTION OPHTHALMIC PHARMACEUTICALS,
    3. OTC OPHTHALMIC PHARMACEUTICALS
  7. GLOBAL ANTI-INFECTIVE OPHTHALMIC, BY REGION
    1. NORTH AMERICA
      1. US
      2. CANADA
      3. MEXICO
    2. EUROPE
      1. GERMANY
      2. FRANCE
      3. UK
      4. ITALY
      5. RUSSIA
      6. REST OF EUROPE
    3. APAC
      1. CHINA
      2. SOUTH KOREA
      3. JAPAN
      4. INDIA
      5. AUSTRALIA
      6. ASEAN
      7. REST OF APAC
    4. MIDDLE EAST & AFRICA
      1. SAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. TURKEY
      5. REST OF MEA
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF MEA
      3. ARGENTINA
      4. REST OF SOUTH AMERICA
  8. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
      1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
  9. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
      1. SANTEN PHARMACEUTICAL
      2. MERCK AND CO.
      3. ROCHE
      4. PFIZER
      5. ALLERGAN
      6. NOVARTIS

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla